www.clarametyx.comHealthcare / BioTech & PharmaFounded: 2019
Clarametyx Biosciences is a developer of immune therapies in the replacement of antibiotics. With a mission to treat life-threatening infections and reduce antibiotic resistance, their platform works to protect bacteria with pathogen-agnostic biologic technology. Key focus areas of the company include clinical development of moderate to severe pneumonia and treatment for chronic diseases like cystic fibrosis. Clarametyx Biosciences was founded by Michael Triplett and Peter Kleinhenz in 2020 and is headquartered in Columbus, OH.
View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Clarametyx Biosciences.
Become part of the Secondary Marketplace, catering to both individual and institutional investors.